fda panel recommends full approval for biogen eisai alzheimers drug.

us fda panel back traditional approval for eisai-biogens alzheimers drug leqembi. a panel of expert advisers on friday unanimously agreed that a late-stage clinical trial of eisai and biogens leqembi verified the benefit of the treatment for alz

us fda panel backs approval for eisai-biogen alzheimers drug leqembi.

fda panel weighs us approval for alzheimers drug from eisai and biogen. a panel of expert advisers on friday began their meeting to discuss whether to recommend traditional United States regulatory approval for eisai and biogens new alzheimers d

fda panel to debate us approval for alzheimers drug from eisai and biogen. a panel of experts on friday will discuss whether to recommend traditional United States regulatory approval for eisai and biogens new alzheimers drug leqembi a move expe

biotech stock roundup: gsk provides updates biogen to discontinue study & more. it was a busy week for the biotech sector with loads of data presentations at the 2023 american society of clinic

biogen (biib) eisais alzheimer drug likely to get full fda nod. the fda issued briefing documents on biogen&rsquo.s biib alzheimer&rsquo.s disease (&ldquo.ad&rdquo.) drug leqembi (lecanemab) fo

fda signals support for eisai-biogen alzheimers drug data confirms benefits for complete approval. fda peripheral and central drugs advisory committee is meeting friday (june 9) to discuss a supplemental marketing application for leqembi (lecanemab) submi

baird reiterates biogen (biib) prior recommendation. fintel reports that on june 7 2023 baird reiterated coverage of biogen (nasdaq:biib) with a outperform recommendation.

fda staff say eisais alzheimers drug may get full approval despite concerns. staff reviewers of the United States food and drug administration (fda) said on wednesday that eisai and biogens alzheimers drug leqembi may still be eligible for a ful

fda staff say eisais alzheimers drug can get full approval despite safety concerns. staff reviewers of the United States food and drug administration (fda) said on wednesday that eisai and biogens alzheimers drug leqembi could still be eligible

biogen gains on super clean fda docs on alzheimers drug ahead of adcom vote.

$100 invested in biogen 15 years ago would be worth this much today. biogen (nasdaq:) has outperformed the market over the past 15 years by 3.97% on an annualized basis producing an average annual return of 11.92%. currently biogen has a market capitaliza

rbc capital reiterates biogen (biib) outperform recommendation. fintel reports that on june 2 2023 rbc capital reiterated coverage of biogen (nasdaq:biib) with a outperform recommendation.

goldman sachs maintains biogen at buy with a price target of $398.00.

piper sandler maintains biogen (biib) overweight recommendation. fintel reports that on june 1 2023 piper sandler maintained coverage of biogen (nasdaq:biib) with a overweight recommendation.

biogen unusual options activity for may 26. someone with a lot of money to spend has taken a ish stance on ). and retail traders should know. we noticed this today when the big position showed up on publicly available options history that we track here

heres why biogen (biib) stock is up 12.6% this year so far. biogen biib has an interesting pipeline with key assets in alzheimer&rsquo.s. biogen is exploring both early to mid-stage assets and late-stage assets to build its pipeline.

biogen : canada accepts new drug submission for lecanemab as treatment for early alzheimers disease. (rttnews) - eisai co. ltd. and biogen inc. (biib) said that health canada has accepted a new drug submission or nds for lecanemab (brand name in

3 reasons to buy biogen stock (and 1 to sell). biogen (nasdaq: biib) has been a polarizing stock to own over the past few years. aduhelms accelerated approval sent the stock soaring a few years ago but after controversy surrounding its approval

argus research maintains biogen (biib) buy recommendation. fintel reports that on may 11 2023 argus research maintained coverage of biogen (nasdaq:biib) with a buy recommendation.

(biib) - analyzing biogens short interest. ) short percent of float has risen 7.59% since its last report. the company recently reported that it has

biogen unusual options activity. someone with a lot of money to spend has taken a bearish stance on ). and retail traders should know. we noticed this today when the big position showed up on publicly available options history that we track here at benz

b of a securities maintains biogen (biib) neutral recommendation. fintel reports that on may 4 2023 b of a securities maintained coverage of biogen (nasdaq:biib) with a neutral recommendation.

$1000 invested in biogen 15 years ago would be worth this much today. biogen (nasdaq:) has outperformed the market over the past 15 years by 4.42% on an annualized basis producing an average annual return of 11.92%. currently biogen has a market capitaliz

notable wednesday option activity: biib gpre chk. looking at options trading activity among components of the russell 3000 index there is noteworthy activity today in biogen inc (symbol: biib) where a total volume of 5602 contracts has been

biogen unusual options activity for may 03. a whale with a lot of money to spend has taken a noticeably bearish stance on looking at options history for biogen (nasdaq:) we detected 11 strange trades. if we consider the specifics of each trade it is ac

biogen recent insider activity. ) reported a large insider sell on may 2 according to a new sec filing. United States securities and exchange commission on tues

biogen up as guggenheim upgrades citing full approval for leqembi.

guggenheim upgrades biogen (biib). fintel reports that on may 1 2023 guggenheim upgraded their outlook for biogen (nasdaq:biib) from neutral to buy .